Formoterol — Discount Pricing

Other medications in Respiratory & Allergies

• Guaifenesin
• Hydroxyzine
• Ivacaftor
• Levalbuterol
• Levocetirizine
• Lumacaftor-Ivacaftor
• Mepolizumab
• Methylprednisolone IV

About Formoterol

Formoterol is a crucial medication for individuals living with chronic respiratory conditions like asthma and COPD, helping them breathe easier and maintain a better quality of life. At TheDrugClub, we understand the importance of affordable access to essential treatments. Discover how our membership can significantly reduce your prescription costs for formoterol and many other medications, making your health journey more manageable.

What is Formoterol and What Does It Treat?

Formoterol is a long-acting beta-agonist (LABA) medication primarily used to treat and prevent bronchoconstriction in people with asthma and chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is often prescribed as a maintenance treatment, meaning it's taken regularly to keep airways open and prevent symptoms. Formoterol can also be used to prevent exercise-induced bronchospasm (EIB), a condition where physical activity triggers asthma symptoms. It's important to note that formoterol is *not* a rescue inhaler and should not be used for sudden breathing problems.

How Does Formoterol Work?

As a LABA, formoterol works by relaxing the smooth muscles surrounding the airways in your lungs. When these muscles tighten, they narrow the airways, making it difficult to breathe. Formoterol binds to specific receptors on these muscle cells, causing them to relax and widen the airways. This bronchodilating effect can last for up to 12 hours, providing sustained relief from symptoms and improving lung function. Because of its long-lasting action, formoterol is typically used once or twice daily, often in combination with an inhaled corticosteroid in a single inhaler for comprehensive asthma or COPD management.

Understanding Typical Costs

The cost of formoterol can vary significantly depending on whether you're prescribed a brand-name product or a generic equivalent, the specific dosage form (e.g., dry powder inhaler, nebulizer solution), and your insurance coverage. Without insurance, a typical monthly supply of formoterol can range from tens to hundreds of dollars, potentially creating a significant financial burden. Brand-name versions are generally more expensive than their generic counterparts. These costs can be a major barrier to consistent treatment, which is vital for

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Formoterol is approved for (FDA label)

Formoterol fumarate inhalation solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. ( 1.1 ) Important limitations of use: Formoterol fumarate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. ( 1.2 , 5.2 ) Formoterol fumarate inhalation solution is not indicated to treat asthma. ( 1.2 ) 1.1 Maintenance Treatment of COPD Formoterol fumarate inhalation solution is indicated for the long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. 1.2 Important Limitations of Use Formoterol fumarate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease [see WARNINGS AND PRECAUTIONS (5.2) ]. Formoterol fumarate inhalation solution is not indicated to treat asthma.

Source: Read the full FDA label on DailyMed. Label effective date: May 1, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Formoterol (FDA label)

Formoterol fumarate inhalation solution is supplied as a sterile solution for nebulization in low-density polyethylene unit-dose vials. Each vial contains formoterol fumarate dihydrate, USP equivalent to 20 mcg/2 mL of formoterol fumarate. Inhalation Solution (unit dose vial for nebulization); 20 mcg/2 mL solution ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 35538d89-a984-4335-acdf-85a893f51eee. SPL document ID: 7b9fb2fd-635e-47d6-91f3-b1fca2b9dc2a. Label effective date: May 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Formoterol (FDA label)

Long-acting beta 2 -adrenergic agonists, such as formoterol fumarate inhalation solution, as monotherapy (without an inhaled corticosteroid) for asthma increase the risk of asthma-related events. Formoterol fumarate inhalation solution is not indicated for the treatment of asthma [see WARNINGS AND PRECAUTIONS (5.1) ]. Most common adverse reactions ( > 2% and more common than placebo) are diarrhea, nausea, nasopharyngitis, dry mouth, vomiting, dizziness, and insomnia ( 6.2 ) To report SUSPECTED ADVERSE REACTIONS, contact Lifestar Pharma LLC at 1-888-995-4337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Beta 2 -Agonist Adverse Reaction Profile Adverse reactions to formoterol fumarate inhalation solution are expected to be similar in nature to other beta 2 -adrenergic receptor agonists including: angina, hypertension or hypotension, tachycardia, arrhythmias, nervousness, headache, tremor, dry mouth, muscle cramps, palpitations, nausea, dizziness, fatigue, malaise, insomnia, hypokalemia, hyperglycemia, and metabolic acidosis. 6.2 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 35538d89-a984-4335-acdf-85a893f51eee. SPL document ID: 7b9fb2fd-635e-47d6-91f3-b1fca2b9dc2a. Label effective date: May 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.